| Literature DB >> 25705142 |
H F Youssef1, W H Hegazy2, H H Abo-Almaged1, G T El-Bassyouni3.
Abstract
The core-shell method is used as a novel synthetic process of micronized Ti-Zeolite Na-A which involves calcination at 700°C of coated Egyptian Kaolin with titanium tetrachloride in acidic medium as the first step. The produced Ti-coated metakaolinite is subjected to microwave irradiation at low temperature of 80°C for 2 h. The prepared micronized Ti-containing Zeolites-A (Ti-Z-A) is characterized by FTIR, XRF, XRD, SEM, and EDS elemental analysis. Ag-exchanged form of Ti-Z-Ag is also prepared and characterized. The Wt% of silver exchanged onto the Ti-Zeolite structure was determined by atomic absorption spectra. The in vitro cytotoxic activity of Ti-Z-Ag against human hepatocellular carcinoma cell line (HePG2), colon cell line carcinoma (HCT116), lung carcinoma cell line (A549), and human Caucasian breast adenocarcinoma (MCF7) is reported. The results were promising and revealed that the exchanged Ag form of micronized Ti-Zeolite-A can be used as novel antitumor drug.Entities:
Year: 2015 PMID: 25705142 PMCID: PMC4332468 DOI: 10.1155/2015/428121
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Figure 1FTIR for the parent Kaolin before (Ti-K) and after (Ti-MK) calcination, Ti-Zeolite Na-A before (Ti-Z-A) and after silver substitution (Ti-Z-Ag).
Infrared bands (cm−1) for Ti-K, Ti-MK, Ti-Zeolite Na-A, and Ti-Zeolite Ag-A.
| Kaolin | Metakaolin coated with titanium | Zeolite incorporated with titanium | Zeolite incorporated with titanium and silver |
|---|---|---|---|
| 1112sh, Si–O | 1088s, Si–O | 997s, Si–O(Si), and Si–O(Al) | 1030b, Si–O(Si), and Si–O(Al) |
| 1091s, Si–O | 794m, Al–O | 686m, Si–O–Si, and Anatase | 692m, Si–O–Si, and Anatase |
| 1065s, Si–O | 691w, Anatase | 547m, Si–O–Si, and O–Si–O | 606m, Si–O–Si, and O–Si–O |
| 1022s, Si–O | 463sh, Anatase | 460m, O–Si–O, and Anatase | 465m, O–Si–O, and Anatase |
| 794w, Si–O–Si | 794sh, Si–O–Si | 3421vb, O–H | 3441s, O–H |
| 530m, AlVI–O | 530sh, AlVI–O | 1652m, O–H | 1633m, O–H |
| 467m, Si–O | |||
| 442sh, Si–O |
Chemical analysis of the starting Kaolinite and Ti-treated form [37].
| Oxides | Kaolinite Wt% | Ti-coated metakaolinite |
|---|---|---|
| SiO2 | 50.54 | 53.33 |
| Al2O3 | 31.48 | 32.64 |
| TiO2 | 2.26 | 7.18 |
| Fe2O3 | 1.87 | 1.97 |
| MgO | 0.90 | 1.02 |
| ZnO | 0.01 | 0.06 |
| CaO | 0.66 | 0.85 |
| Na2O | 0.10 | 0.11 |
| K2O | 0.07 | 0.07 |
| P2O5 | 0.08 | 0.09 |
| SO3 | 0.08 | 0.02 |
| Cl | 0.02 | 0.23 |
| L.O.I | 11.75 | 2.40 |
|
| ||
| Total | 100 | 100 |
Figure 2XRD pattern of the calcined Ti-containing Kaolin (Ti-metakaolinite) after calcination to metakaolinite (TMK) at 700°C/4 h.
Figure 3X-ray pattern for Ti-Zeolite (Ti-Z-A) and its silver-exchanged form (Ti-Z-Ag).
Figure 4SEM micrographs for Ti-Z-A and its EDS analysis. Lc: late crystals = minute crystals. and Ec: early crystals = big crystals.
EDX analysis for Ti-Zeolite (Ti-ZA).
| Element | Minute cubes | Large cubes | ||
|---|---|---|---|---|
| Wt% | At% | Wt% | At% | |
| O K | 36.14 | 50.38 | 40.50 | 53.95 |
| NaK | 13.03 | 12.63 | 13.50 | 12.52 |
| Al K | 17.29 | 14.29 | 17.82 | 13.65 |
| Si K | 22.03 | 17.49 | 22.92 | 17.39 |
| Ti-K | 9.23 | 4.30 | 4.55 | 2.02 |
| Fe K | 2.27 | 0.91 | 1.25 | 0.48 |
|
| ||||
| Total | 100.00 | 100 | 100 | 100 |
EDX percentage of atomic constituents (At%) for starting precursor (Ti-MK), reference Zeolite, and Ti-Zeolite crystals of different generations.
| At.% ratio | Ti-MK* | Ref. Zeolite** | Ti-Zeolite | |
|---|---|---|---|---|
| Minute cube | Large cube | |||
| Si/Al | 1.28 | 1.03 | 1.29 | 1.27 |
| Si/Ti | 5.72 | 17.11 | 4.07 | 8.61 |
*Ti-metakaolinite, that is, Ti-coated Kaolin after calcination (EDS analysis is not included).
**Zeolite prepared from the starting kaolin before coating with titanium.
Figure 5SEM and EDS chemical analysis for the Ag-substituted Ti-Z-A.
EDX microanalysis of the Ag-substituted Ti-Z-A.
| Element | Wt% | At% |
|---|---|---|
| O K | 28.20 | 50.03 |
| NaK | 3.83 | 4.72 |
| Al K | 14.07 | 14.81 |
| Si K | 20.82 | 21.04 |
| Ti-K | 2.08 | 1.23 |
| Ag K | 31.01 | 8.16 |
|
| ||
| Total | 100 | 100 |
Cytotoxic screening of the novel synthesized Ti-Zeolite-A exchanged by Ag against the tested human cancer cell lines.
| Human cancer cell lines | Ti-Zeolite-Ag | *Doxorubicin |
|---|---|---|
| LC50 ( | LC50 ( | |
| HePG2 | 15.1 | 37.8 |
| HCT116 | 56.9 | 65.1 |
| A549 | 39.1 | 48.8 |
| MCF7 | 18.8 | 45.02 |
*Positive control adriamycin (doxorubicin).
Figure 6LC50 μM of the prepared Ti-Z-Ag against carcinoma cell line compared with doxorubicin (positive control).